RxDoctor Payments Data

Burhan Yanes, MD

Hematology & Oncology · Kettering, OHNPI 1275572869

Payments from drug & device makers

$14,217in general payments, 2019–2025

Across 398 payments — averaging $35.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • AstraZeneca$3K
  • Novartis$794
  • Daiichi Sankyo Inc.$769
  • Merck$638
  • Johnson & Johnson$363
  • plus $5K from 54 others

What the payments were for

  • Consulting fees$5,77441%
  • Travel & lodging$5764%
  • Food & beverage$7,54753%
  • Education$3192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi11$3,302
AstraZeneca(2 entities)25$3,270
Novartis46$794
Daiichi Sankyo Inc.15$769
Merck30$638
Johnson & Johnson17$363
Bristol Myers Squibb20$333
Incyte Corporation15$301
Gilead(2 entities)10$298
GSK11$275
AbbVie11$264
E.r. Squibb & Sons, L.L.C.13$245
Takeda Pharmaceuticals U.S.A., Inc.8$231
Eisai Inc.11$188
Bayer9$174
Pfizer10$173
Astellas Pharma US Inc10$168
Regeneron Healthcare Solutions, Inc.10$152
EMD Serono, Inc.4$108
Amgen6$106
Octapharma USA, Inc.5$98
Karyopharm Therapeutics Inc.5$95
Boehringer Ingelheim4$89
Ipsen Biopharmaceuticals, Inc5$83
Genmab U.S., Inc.4$80
Lilly USA, LLC4$79
Springworks Therapeutics, Inc.2$77
TG Therapeutics, Inc.1$76
Stemline Therapeutics Inc.4$74
Myriad Genetic Laboratories, Inc.1$70
Rigel Pharmaceuticals, Inc.5$69
Genentech USA, Inc.4$68
Seagen Inc.4$59
Pharmacosmos Therapeutics Inc.2$56
Taiho Oncology, Inc.3$53
Foundation Medicine, Inc.2$51
Deciphera Pharmaceuticals Inc.3$50
Beigene USA, Inc.2$49
AVEO Pharmaceuticals, Inc.2$44
Mirati Therapeutics, Inc.2$43
Tersera Therapeutics LLC1$40
Pharmaessentia USA Corporation2$39
Array Biopharma Inc3$38
Immunocore Limited2$36
Sumitomo Pharma America, Inc.2$32
Tempus AI, Inc2$31
Morphosys, US Inc.2$30
Lexicon Pharmaceuticals, Inc.2$29
Servier Pharmaceuticals LLC2$27
Janssen Scientific Affairs, LLC1$24
Verastem, Inc.1$22
Aadi Bioscience, Inc.1$22
Apellis Pharmaceuticals, Inc.1$20
Exelixis Inc.1$19
Fennec Pharmaceuticals, Inc.1$19
Clovis Oncology, Inc.2$19
Mylan Institutional Inc.1$18
Blueprint Medicines Corporation1$18
Pharmacyclics LLC, An Abbvie Company1$18
Tolmar, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,217 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$2,639,014
Medicare patients
464
Services billed
109,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide34$427,121
Lenalidomide26$334,138
IbrancePalbociclib17$248,244
ImbruvicaIbrutinib11$180,370
EliquisApixaban18$18,141
XareltoRivaroxaban21$16,035
Anagrelide Hcl11$3,727
Tamoxifen Citrate29$704
Oxycodone Hcl23$696
Hydroxyurea33$497
Anastrozole25$487
Warfarin Sodium41$365
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$285
Prednisone37$186
Acyclovir15$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$168$427,12134 claims
PfizerIbrance, Eliquis$173$266,38535 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$18$180,37011 claims
Johnson & JohnsonXarelto$363$16,03521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →